US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Isofol Medical AB (publ) publishes interim report, January–September 2023

GOTHENBURG, Sweden, November 10, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–September 2023 is now available, in Swedish, on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Third quarter, July – September 2023 · Net revenue amounted to TSEK 0 (2,907) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -6,260 (-32,513) · Earnings per share amounted to SEK -0.04 (-0.20) · Cash and cash equivalents as of September

Isofol Medical AB (publ) publishes interim report, January–June 2023

GOTHENBURG, Sweden, August 22, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–June 2023 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Second quarter, April–June 2023 · Net revenue amounted to TSEK 0 (4,027) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -7,507 (-54,033) · Earnings per share amounted to SEK -0.05 (-0.33) · Cash and cash equivalents at June 30 amounted to TSEK 156,767 (277,

Isofol Medical AB (publ) publishes interim report, January–March 2023

GOTHENBURG, Sweden, May 3, 2023 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–March 2023 is now available, in Swedish, on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. First quarter, January–March 2023 · Net revenue amounted to TSEK 721 (4,006) and other revenue to TSEK 23 (1) · The result for the period amounted to TSEK -14,395 (-47,874) · Earnings per share amounted to SEK -0.09 (-0.30) · Cash and cash equivalents on March 31 amounted to

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2022

GOTHENBURG, Sweden, April 6, 2023 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2022 are now available, in Swedish, on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. For further information, please contact Isofol Medical AB (publ)Thomas Andersson, Chief Executive Officer  E-mail: thomas.andersson@isofolmedical.comPhone: +46 (0) 709 44 00 93 Roy Jonebrant, Chief Financial Officer E-mail: roy.jonebrant@

CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023

GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr. Ulf Jungnelius M.D. and Isofol’s Board of Directors have agreed that Ulf will step down as CEO of Isofol on June 1, 2023. Isofol’s Board of Directors will take a decision regarding a new CEO once the company’s future has been determined.The information in the press release is intended for investors. Dr. Ulf Jungnelius M.D. and Isofol have agreed that Ulf will leave his position as CEO of Isofol Medical on June 1, 2023. Until then he will be fully

Final data from the AGENT study confirms topline results

GOTHENBURG, Sweden, November 25, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that analysis of the AGENT study’s final data confirmed topline results presented on August 3, 2022. Moreover, no predictive gene expressions for clinical response could be identified. Isofol is continuing its efforts to terminate the AGENT study in line with applicable ethical and regulatory requirements, complete the final study report for submission to regulatory agencies and prepare a manuscript for a scientific publication. Isofol is in parallel continuing to investigate possible

Isofol Medical AB (publ) publishes interim report, January–September 2022

GOTHENBURG, Sweden, November 11, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January–September 2022 is now available on the company's website, www.isofolmedical.com.The information in the press release is intended for investors. Third quarter, July – September 2022 · Net revenue amounted to TSEK 2,907 (5,154) and other revenue to TSEK 0 (0) · The result for the period amounted to TSEK -32,513 (-51,026) · Earnings per share amounted to SEK -0.20 (-0.32) · Cash and cash equivalents as of September 30

Isofol Medical AB (publ) publishes annual report and corporate governance report for 2021

GOTHENBURG, Sweden, April 27, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), today announced that the company's annual report and corporate governance report for the financial year 2021 are now available on the company's website, www.isofolmedical.com .For further information, please contact Isofol Medical AB (publ)Jarl Ulf Jungnelius, M.D., Chief Executive Officer  E-mail: jungnelius@isofolmedical.com  Phone: +46 (0) 709 16 89 55   Gustaf Albèrt, CFO and deputy CEOE-mail: gustaf.albert@isofolmedical.com

Isofol Medical AB (publ) publishes year-end report, January - December 2021

GOTHENBURG, Sweden, February 24, 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's year-end report for January – December 2021 is now available on the company's website, www.isofolmedical.com .Fourth quarter, October –December 2021 · Net revenue amounted to TSEK 4,704 (18,680) and other revenue to TSEK 0 (18) · The result for the period amounted to TSEK -61,170 (-54,659) · Earnings per share amounted to SEK -0.38 (-0.66) · Cash and cash equivalents on December 31 amounted to

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe